Projects per year
Project Details
Description
Summary
The Chemical Biology and Therapeutics Innovation Core (Core D) referred in the PP text as “Therapeutics
Core” will provide services to the four projects of this Program Project and work collaboratively with several
project leaders to accomplish the innovation component.
The long-term goal of this core is to provide support for the needs of the individual projects on synthesizing
currently available novel autophagy modulators, validating compounds from screening and hit-to-lead medicinal
chemistry optimization targeting different autophagy pathways and assessing the impact of these compounds
by modulating autophagy in Alzheimer’s disease and Alzheimer’s disease-related dementias.
The specific aims of this core are: 1) to provide a chemical biology facility that will assist the investigators of
the program projects and cores to have access to novel modulators of autophagy and information for their proper
formulation and use in cellular and in vivo mouse studies. 2) to facilitate chemical screening approaches, hit
selection, hit validation, and target identification and engagement using chemical biology approaches 3) to work
with project leaders for the validation and expansion of hit compounds and hit-to-lead optimization using
principles of medicinal chemistry.
Components: 1) The chemical biology unit will provide chemical synthesis of compounds and chemical
probes, compound distribution, analytical characterization of compounds and assistance with the solubilization,
formulation and assay of compounds 2) The innovation unit will validate, optimize and implement different
chemical modulators of autophagy using medicinal chemistry towards proof-of-concept in vivo studies for
Alzheimer’s disease and Alzheimer’s disease-related dementias.
Services: the core will assist with the design, chemical synthesis, purification and analytical characterization
of novel autophagy modulators, the design and synthesis of chemical probes for target identification and
engagement studies in vivo, validation of hits and hit expansion studies by computational drug design
approaches, design and synthesis of focused chemical libraries for structure-activity relationships studies,
medicinal chemistry for hit-to-lead optimization, advice and assistance with solubilization, proper use in assays,
pharmacokinetic studies, and formulation procedures for evaluation of compounds in vivo.
Relevance: This core is essential for the translational efforts of this PP to develop pre-clinical proof-of-concept
on the validity of targeting autophagy as an effective intervention to prevent or delay onset of Alzheimer’s disease
pathology. We anticipate that lead molecules generated and tested with the core could set the basis for future
development clinical drugs for this devastating age-related disorder.
Status | Active |
---|---|
Effective start/end date | 4/1/20 → 3/31/24 |
Funding
- National Institute on Aging: $373,804.00
- National Institute on Aging: $374,640.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
Projects
- 1 Active
-
Autophagy in aging: testing geroscience in Alzheimer's disease
Cuervo, A. M., Bravo Cordero, J. J., Gavathiotis, E., Macian-Juan, F., Santambrogio, L. & Singh, R.
2/15/09 → 3/31/24
Project: Research project